Click Therapeutics raises further $52M to build up digital therapeutics pipeline for depression, insomnia, smoking cessation and more

by

Get­ty Images

With Sanofi still on board, Click Ther­a­peu­tics clos­es $52M series B for dig­i­tal ther­a­peu­tics in depres­sion, chron­ic pain and more (Fierce Biotech):

Anoth­er medtech devel­op­er’s plans to cre­ate dig­i­tal ther­a­peu­tics to treat a wide range of ill­ness­es are click­ing into place, thanks to a third mul­ti­mil­lion-dol­lar invest­ment in Click Ther­a­peu­tics in bare­ly a year.

Click has already val­i­dat­ed and begun the com­mer­cial launch of its first prod­uct, Click­o­tine, a mobile soft­ware pro­gram for smok­ing ces­sa­tion … Sev­er­al more of Click’s app-based therapeutics—all of which will require a physician’s pre­scrip­tion and there­fore FDA clearance—are under­go­ing clin­i­cal tri­als and run the gamut of med­ical tar­gets. The fur­thest along of these is a pro­gram to treat major depres­sive dis­or­der, devel­oped in part­ner­ship with Otsu­ka. A phase 3 tri­al of the pro­gram host­ed on Verily’s Base­line plat­form is now study­ing the abil­i­ties of sev­er­al cog­ni­tive exer­cis­es to lessen the symp­toms of depression.

Close behind in phase 2 tri­als are Click’s work to treat migraine and schizophrenia—the lat­ter of which is a col­lab­o­ra­tion with Boehringer Ingelheim—as well as the clev­er­ly named Clicka­di­an, for insom­nia, and Click­heart, for acute coro­nary syn­drome. Dig­i­tal ther­a­peu­tics for over­ac­tive blad­der, chron­ic low­er back pain and obe­si­ty, mean­while, are still in the ear­li­est stages of clin­i­cal study.

The Announcement:

Click Ther­a­peu­tics Com­pletes $52 Mil­lion Series B Financ­ing Co-Led by H.I.G. Bio­Health Part­ners and Accelmed Part­ners (press release):

Click Ther­a­peu­tics, Inc. (“Click”), a leader in Dig­i­tal Ther­a­peu­tics™ as pre­scrip­tion med­ical treat­ments, today announced that it has closed a $52 mil­lion upsized Series B financ­ing. The financ­ing round was co-led by new investors H.I.G. Bio­Health Part­ners (“H.I.G. Bio­Health”) and Accelmed Part­ners II (“Accelmed”), with par­tic­i­pa­tion from Health Cat­a­lyst Cap­i­tal, Rev­e­la­tion Part­ners, and a top biotech­nol­o­gy hedge fund, and from exist­ing investors Sanofi Ven­tures, K2 HealthVen­tures, Hik­ma Ven­tures, and Ridgetop Health. Pro­ceeds from the Series B financ­ing will be used to accel­er­ate the devel­op­ment and com­mer­cial­iza­tion of Click’s inter­nal pre­scrip­tion dig­i­tal ther­a­peu­tic pipeline and advance Click’s plat­form capabilities.

Click’s pipeline of inno­v­a­tive dig­i­tal ther­a­peu­tics spans mul­ti­ple ther­a­peu­tic areas, from psy­chi­a­try and chron­ic pain to car­diometa­bol­ic and autoim­mune dis­or­ders. In addi­tion to its inter­nal pipeline pro­grams, Click has entered into land­mark col­lab­o­ra­tion agree­ments with Otsu­ka to devel­op and com­mer­cial­ize a pre­scrip­tion dig­i­tal ther­a­peu­tic for treat­ment of Major Depres­sive Dis­or­der (MDD), and with Boehringer Ingel­heim to devel­op and com­mer­cial­ize a pre­scrip­tion-based dig­i­tal ther­a­peu­tic to aid in the treat­ment of schizophrenia.

News in Context: